News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?
Amol Akhade/hiranandanihospital.org
Apr 16, 2025, 17:55

Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?

Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn:

“LET’S PLAY DEVIL’S ADVOCATE:

Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer? Tannock et al. JCO_ASCO argue –

Modest iDFS, no OS benefit ( yet ) , high toxicity and censoring bias.

I broke it down—with counterarguments .

Do Check this out.”

Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor

Authors: Ian F. Tannock, Qamar J. Khan, and Tito Fojo 

Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?

More posts featuring Amol Akhade.

Amol Akhade Breast Cancer cancer cancer treatment Ian F. Tannock OncoDaily Oncology Qamar J. Khan Tito Fojo
Special Coverage
Blog
Apr 19, 2025, 17:53
Cancer Nutrition Tips: Pink Africa Foundation Highlights Healing Benefits
Blog
Apr 19, 2025, 17:21
Exploring the integration of patient-reported outcome measures in clinical practice
Blog
Apr 19, 2025, 17:17
Join our Networks and Working Groups to learn, network and grow - SIOP
Blog
Apr 19, 2025, 17:14
Re-irradiation revolution: Maximising technical advances in imaging, biology and dose evaluation at ESTRO 2025
Blog
Apr 19, 2025, 17:02
New whitepaper on navigation services and reimbursement success - Florida Cancer Specialists and Research Institute
Blog
Apr 19, 2025, 17:01
Chiara Mercinelli: Honored to have been selected for the ASCO 2025 Merit Award
Blog
Apr 19, 2025, 16:48
How EveryGrant helps organizations build impactful grant programs - Conquer Cancer, the ASCO Foundation
Blog
Apr 19, 2025, 16:44
Agenus to Reveal Phase 1 HCC Immunotherapy Data at AACR 2025
Blog
Apr 19, 2025, 16:36
Bilal Awad: Knowledge, attitudes, and self-efficacy regarding palliative care among Palestinian nurses in intensive care units
Blog
Apr 19, 2025, 16:23
Toufic Kachaamy: Thrilled to give two talks on cancer ablation at DDW2025
Blog
Apr 19, 2025, 16:23
Elvina Almuradova: Olaparib improved ORR and PFS in BRCA-mutated PSR ovarian cancer, but no OS benefit
Blog
Apr 19, 2025, 16:12
Cristian Massacesi: Visiting our AstraZeneca team in Germany to talk oncology ambitions